Clinical trials: Head and Neck Tumours
Head and Neck Neoplasms
The EMINENCE Study - PET/MR Imaging of Head Neck Cancer
Head and neck cancers (HNC) often receive radiotherapy as part of their treatment. However, unacceptable failure rates and severe side effects remain a challenge.
- Trial name
- EMINENCE (NCT04612075)
- Testing
- FDG-PET/MRI
- Where
- 2 sites in Norway
- Volunteers
- 390 people
- Sponsor
- Norwegian University of Science and Technology
Esophageal Cancer, Head and Neck Cancer
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
RATIONALE: Studying samples of sputum and tissue in the laboratory from patients with dysplasia or cancer may help doctors identify and learn more about biomarkers related to cancer.
- Conditions
- Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Precancerous Condition
- Trial name
- NCT00900419
- Testing
- immunohistochemistry staining method, laboratory biomarker analysis, sputum cytology
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- University of Colorado, Denver
Head and Neck Cancer, Oral Complications
Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer
RATIONALE: Cevimeline may be effective in treating dry mouth that is caused by radiation therapy for head and neck cancer. It is not yet known if cevimeline is more effective than no therapy in treating dry mouth caused by…
- Conditions
- Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00017511
- Testing
- cevimeline hydrochloride
- Where
- 71 sites in United States
- Sponsor
- Daiichi Sankyo
KRAS G12D Mutation, Advanced Solid Cancer
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation.
- Trial name
- NCT07023731
- Testing
- ARV-806
- Where
- 14 sites in United States
- Volunteers
- 76 people
- Sponsor
- Arvinas Inc.
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Esophageal Cancer
Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer
This is a multi-center, open label, randomized phase II trial for patients with previously untreated metastatic or locally advanced esophagogastric cancer, using a pick the winner design to identify the best combination therapy…
- Trial name
- LyRICX (NCT03764553)
- Testing
- Liposomal Irinotecan, Carboplatin, Capecitabine
- Where
- 34 sites in Netherlands
- Volunteers
- 320 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study
This phase IV trial is evaluating whether morning versus afternoon administration of standard of care immunotherapy impacts its effectiveness in treating patients with solid tumors that may have spread from where it first started…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma
- Trial name
- NCT07405086
- Testing
- Biospecimen Collection, Immune Checkpoint Inhibitor
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- OHSU Knight Cancer Institute
Radiotherapy, PD-1 Inhibitor
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma
This is a single-arm, multicenter, prospective, open-label phase II clinical trial of multi-target radiotherapy combined with PD-1 monoclonal antibody and capecitabine maintenance therapy treating oligometastatic nasopharyngeal…
- Conditions
- Radiotherapy, PD-1 Inhibitor, Capecitabine, Nasopharyngeal Carcinoma
- Trial name
- NCT05290194
- Testing
- SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1 inhibitor, Capecitabine
- Where
- China
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma
Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma
This is an open-label, multi-center, phase II trial to evaluate the safety and efficacy of postponing or omitting re-irradiation after systemic therapy with tislelizumab and chemotherapy in patients with unresectable recurrent…
- Conditions
- Recurrent Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Chemotherapy Effect, Immunotherapy
- Trial name
- RETICULA-NPC (NCT04921995)
- Testing
- Tislelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Prostate Cancer (Post Prostatectomy), Anal Cancer
Assessment of New Radiation Oncology Technologies and Treatments
The Trans Tasman Radiation Oncology Group (TROG) has been commissioned by the Department of Health and Ageing to undertake a project to assess new Radiation Oncology Technology and Treatments.
- Conditions
- Prostate Cancer (Post Prostatectomy), Anal Cancer, Nasopharyngeal Cancer, Intermediate Risk Prostate Cancer
- Trial name
- ANROTAT (NCT01379872)
- Testing
- Non-Interventional Study
- Where
- 15 sites in Australia
- Volunteers
- 138 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Head and Neck Squamous Cell Carcinoma
Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma
Multi-center, open-label, non-randomized, non-comparative two-cohort study for patients with locally-advanced squamous cell carcinoma arising from the larynx, hypopharynx, oropharynx (Stage III, IVA and IVB according to 8th…
- Trial name
- RADIAN (NCT05784012)
- Testing
- Dostarlimab, Niraparib, cisplatin plus radiotherapy
- Where
- 7 sites in Spain
- Volunteers
- 34 people
- Sponsor
- Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Nasopharyngeal Carcinoma
Adjuvant Treatment of Apatinib in Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of apatinib for adjuvant treatment of High-risk metastasis of nasopharyngeal carcinoma after IMRT with concurrent chemotherapy,including progression-free survival (PFS),evaluation…
- Trial name
- NCT03612219
- Testing
- Apatinib mesylate tablet, Intensity-modulated radiation therapy (IMRT), Cisplatin
- Where
- 6 sites in China
- Volunteers
- 240 people
- Sponsor
- Wei Jiang
Radiotherapy; Complications, Head and Neck Cancer
Individualization of Nutritive Sensory Support Of Radiation Therapy
Nutritional deficiency and subsequent weight loss in patients with head and neck cancer is a common problem and a negative predictor of treatment outcomes and mortality, as well as quality of life.
- Trial name
- NCT05046028
- Testing
- Oral nutritional supplements (ONS) with a cooling effect + ONS without a sensor component and taste + standard diet, ONS without a sensor component and taste + standard diet, Standard diet
- Where
- Russia
- Volunteers
- 100 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Head & Neck Squamous Cell Carcinoma
A Study of Adaptive Radiotherapy of Head-neck Cancer Using Daily Replanning and Optimization of the Treatment Plan.
Radiotherapy of head-neck cancer is associated with significant side effects. Using daily online adaptive radiotherapy to account for the changing anatomy, radiation to organs at risk can be lowered.
- Trial name
- DART-HN (NCT07506902)
- Testing
- Daily online adaptive radiotherapy
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
This primary purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE) and preferred dosing schedule of LJM716 given by IV infusion in adult patients with squamous cell…
- Conditions
- HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT01598077
- Testing
- LJM716
- Where
- 8 sites in United States, Canada and 3 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Barrett Esophagus, Esophageal Cancer
Molecular Fluorescence Endoscopy of (Pre)Malignant Esophageal Lesions
To improve detection of esophageal (pre)malignant lesions during surveillance endoscopy of patients at risk of developing malignancies, for example in Barrett's Esophagus (BE), there is a need for better endoscopic visualization…
- Conditions
- Barrett Esophagus, Esophageal Cancer, Dysplasia in Barrett Esophagus
- Trial name
- EAGLE (NCT03205501)
- Testing
- IV-administation of EMI-137, Molecular Fluorescence Endoscopy platform
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen
Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy
A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
This study aimed to compare the efficacy of neoadjuvant low-dose radiotherapy combined with targeted therapy and immunotherapy versus targeted therapy and immunotherapy alone in patients with resectable head and neck squamous…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy, Targeted Therapy
- Trial name
- NCT07040956
- Testing
- Tislelizumab, Afatinib, Low dose radiotherapy
- Where
- China
- Volunteers
- 98 people
- Sponsor
- West China Hospital
Laryngeal Neoplasm
The Efficacy of Superficial Cervical Block Application in Postoperative Analgesia Management in Patients Undergoing Total Laryngectomy and Bilateral Neck Dissection
The goal of this clinical trial is to evaluate the efficacy of the superficial cervical block in postoperative pain management for patients undergoing total laryngectomy and bilateral neck dissection.
- Trial name
- NCT06852651
- Testing
- Superficial Cervical Block (SCB) Group
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer
Neoadjuvant Immunochemotherapy and Postoperative Adjuvant Immunotherapy for Head and Neck Squamous Cell Carcinoma Invading the Skull Base
This prospective, single-arm, Phase II clinical trial aims to evaluate the efficacy and safety of tislelizumab combined with chemotherapy as neoadjuvant therapy and postoperative adjuvant immunotherapy in patients with skull…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Skull Base--Cancer, Neoadjuvant Chemoimmunotherapy, Objective Response Rate
- Trial name
- NCT07145931
- Testing
- Neoadjuvant chemoimmunotherapy, Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Neoplasms, Non-small-cell Lung Cancer
A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.
The purpose of this study is to learn about the: safety (the effect of the study medicine on the participant's body), effects of the study medicine alone or in combination with sasanlimab - the best amount of the study medicine.
- Conditions
- Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma
- Trial name
- NCT06546553
- Testing
- PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo)
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.